RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RAD001 is approved by the U.S Food and Drug Administration (FDA) to treat advanced kidney
cancer. This drug has also been used in other research studies to evaluate its effectiveness
in other cancers. Information from these research studies suggests that RAD001 may help to
decrease the growth and development of tumor cells by reducing the blood supply that tumors
need to grow. In this research study, we are trying to determine the safety of RAD001 when
given to people with locally advanced head and neck cancer in combination with cisplatin and
radiation. We are also looking for the highest dose of RAD001 that can be given to people
safely.